Compositions and methods for enzymatic disruption of bacterial biofilms
View Patent ↗Provided herein are methods to inhibit or disrupt a bio film comprising contacting the bio film with an agent that cleaves the Holliday junction (HJ) structure in the bio film.
1. A method to inhibit or disrupt a biofilm comprising contacting the biofilm with an agent that cleaves the Holliday junction (HJ) structure in the biofilm, wherein the agent is an HJ-specific endonuclease, thereby inhibiting or disrupting said biofilm.
2. The method of claim 1 , wherein the contacting is in vitro or in vivo.
3. The method of claim 1 , wherein the HJ-specific endonuclease is a RuvABC polypeptide, a RusA polypeptide, or both.
4. The method of claim 3 , wherein the RusA polypeptide comprises the polypeptide MVNTYSITLPWPPSNNRYYRHNRGRTHVSAEGQAYRDNVARIIKNAMLDIGLAMPVKI RIECHMPDRRRRDLDNLQKAAFDALTKAGFWLDDAQVVDYRVVKMPVTKGGRLELTI TEMGNEA (SEQ ID NO: 1), or an equivalent thereof.
5. The method of claim 3 , wherein the RuvABC polypeptide comprises the polypeptides MIGRLRGIBEKQPPLVLIEVGGVGYEVHMPMTCFYELPEAGQEAIVFTHFVVREDAQLL YGFNNKQERTLFKELIKTNGVGPKLALAILSGMSAQQFVNAVEREEVGALVKLPGIGKK TAERLIVEMKDRFKGLHGDLFTPAADLVLTSPASPATDDAEQEAVAALVALGYKPQEAS RMVSKIARPDASSETLIREALRAAL (SEQ ID NO: 4); MIEADRLISAGTTLPEDVADRAIRPKLLEEYVGQPQVRSQMEIFIKAAKLRGDALDHLLIF GPPGLGKTTLANIVANEMGVNLRTTSGPVLEKAGDLAAMLTNLEPHDVLFIDEIHRLSP VVEEVLYPAMEDYQLDIMIGEGPAARSIKIDLPPFTLIGATTRAGSLTSPLRDRFGIVQRL EFYQVPDLQYIVSRSARFMGLEMSDDGALEVARRARGTPRIANRLLRRVRDFAEVKHD GTISADIAAQALDMLNVDAEGFDYMDRKLLLAVIDKFFGGPVGLDNLAAAIGEERETIE DVLEPYLIQQGFLQRTPRGRMATTRAWNHFGITPPEMPA (SEQ ID NO: 2); and MASAIILGIDPGSRVTGYGVIRQVGRQLSYLGSGCIRTKVDDLPSRLKLIYAGVTEIITQFQ PDYFAIEQVFMAKNADSALKLGQARGVAIVAAVNQELPVFEYAARQVKQTVVGIGSAE KSQVQHMVRTLLKLPANPQADAADALAIAITHCHVSQNAMQMSESRLNLARGRLRA (SEQ ID NO: 3), or an equivalent of each thereof, wherein an equivalent contains the mutated amino acids as shown in the bold font.
6. The method of claim 1 , wherein the biofilm is caused by one or more of uropathogenic Escherichia coli (UPEC), nontypeable Haemophilus influenzae (NTHI), S. epidermidis, Streptococcus agalactiae, Neisseria meningitidis, Treponema denticola, Treponema pallidum, Burkholderia cepacia, Burkholderia pseudomallei, Moraxella catarrhalis, Streptococcus pneumoniae, Streptococcus pyogenes, Pseudomonas aeruginosa, Mycobacterium tuberculosis, Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa , or Enterobacter species.
7. The method of claim 1 , further comprising contacting the biofilm with an antimicrobial agent or a deoxyribonuclease (DNase).
8. A method to inhibit or disrupt a biofilm or treat a disease or condition incident to a biofilm infection in a subject in need thereof, comprising administering to the subject an effective amount of an agent that cleaves the Holliday junction (HJ) structure in the biofilm, wherein the agent is an HJ-specific endonuclease, thereby inhibiting or disrupting said biofilm.
9. The method of claim 8 , wherein the administration is local or systemic.
10. The method of claim 8 , wherein the HJ-specific endonuclease is a RuvABC polypeptide or a RusA polypeptide or both.
11. The method of claim 10 , wherein the RusA polypeptide comprises the polypeptide MVNTYSITLPWPPSNNRYYRHNRGRTHVSAEGQAYRDNVARIIKNAMLDIGLAMPVKI RIECHMPDRRRRDLDNLQKAAFDALTKAGFWLDDAQVVDYRVVKMPVTKGGRLELTI TEMGNEA (SEQ ID NO: 1), or an equivalent thereof.
12. The method of claim 10 , wherein the RuvABC polypeptide comprises the polypeptides MIGRLRGIBEKQPPLVLIEVGGVGYEVHMPMTCFYELPEAGQEAIVFTHFVVREDAQLL YGFNNKQERTLFKELIKTNGVGPKLALAILSGMSAQQFVNAVEREEVGALVKLPGIGKK TAERLIVEMKDRFKGLHGDLFTPAADLVLTSPASPATDDAEQEAVAALVALGYKPQEAS RMVSKIARPDASSETLIREALRAAL (SEQ ID NO: 4); MIEADRLISAGTTLPEDVADRAIRPKLLEEYVGQPQVRSQMEIFIKAAKLRGDALDHLLIF GPPGLGKTTLANIVANEMGVNLRTTSGPVLEKAGDLAAMLTNLEPHDVLFIDEIHRLSP VVEEVLYPAMEDYQLDIMIGEGPAARSIKIDLPPFTLIGATTRAGSLTSPLRDRFGIVQRL EFYQVPDLQYIVSRSARFMGLEMSDDGALEVARRARGTPRIANRLLRRVRDFAEVKHD GTISADIAAQALDMLNVDAEGFDYMDRKLLLAVIDKFFGGPVGLDNLAAAIGEERETIE DVLEPYLIQQGFLQRTPRGRMATTRAWNHFGITPPEMPA (SEQ ID NO: 2); and MASAIILGIDPGSRVTGYGVIRQVGRQLSYLGSGCIRTKVDDLPSRLKLIYAGVTEIITQFQ PDYFAIEQVFMAKNADSALKLGQARGVAIVAAVNQELPVFEYAARQVKQTVVGIGSAE KSQVQHMVRTLLKLPANPQADAADALAIAITHCHVSQNAMQMSESRLNLARGRLRA, (SEQ ID NO: 3) or an equivalent of each thereof, wherein an equivalent contains the mutated amino acids as shown in the bold font.
13. The method of claim 8 , further comprising administering an effective amount of an antimicrobial agent to the subject.
14. The method of claim 8 , wherein the disease or condition is an infection caused by one or more of Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species, uropathogenic Escherichia coli (UPEC), nontypeable Haemophilus influenzae (NTHI), S. epidermidis, Streptococcus agalactiae, Neisseria meningitidis, Treponema denticola, Treponema pallidum, Burkholderia cepacia, Burkholderia pseudomallei, Moraxella catarrhalis, Streptococcus pneumoniae, Streptococcus pyogenes, Pseudomonas aeruginosa , or Mycobacterium tuberculosis ; an infection in upper, mid and lower airway, otitis, sinusitis, bronchitis, exacerbations of chronic obstructive pulmonary disease (COPD), chronic cough, complications of or primary cause of cystic fibrosis (CF) or community acquired pneumonia (CAP).
15. The method of claim 8 , further comprising contacting the biofilm with an antimicrobial agent or a deoxyribonuclease (DNase).
16. The method of claim 8 , wherein the disease is cystic fibrosis and the administration is by inhalation.
17. The method of claim 16 , further comprising contacting the biofilm with an antimicrobial agent or DNase.